– USA, MA – Akoya Biosciences Inc., (NASDAQ: AKYA), The Spatial Biology Company, today announced the appointment of diagnostics industry leader Scott Mendel to its board of directors.
“We are excited and honored to have Scott join Akoya’s Board of Directors,” said CEO, Brian McKelligon. “With more than 25 years of experience as one of the most accomplished executives in the diagnostics industry and a proven track record of transforming innovative technologies into clinical testing solutions, I am confident Scott will bring tremendous insights to Akoya as we continue to advance the company.”
About Scott Mendel
Scott Mendel is currently CEO of GenMark Diagnostics, a highly innovative and successful molecular diagnostics company. In April, the multinational healthcare company Roche acquired GenMark for $1.8 billion. Mr. Mendel joined GenMark as CFO in 2014 and was promoted to CEO in 2020. Prior to GenMark, Mr. Mendel held senior-level leadership positions with The Active Network and GE Healthcare.
“I am delighted to join the board of directors of Akoya, a company that has the potential to transform biomarker discovery and clinical research through the application of its spatial biology platforms,” said Scott Mendel. “Akoya’s cutting-edge solutions enable scientists to visualize how cells are organized and interact within the tissue microenvironment, providing unprecedented understanding of disease progression and treatment response.”
Mr. Mendel earned a B.S. in finance from Indiana University and an M.B.A. from Northwestern University’s Kellogg School of Management.
About Akoya Biosciences
As The Spatial Biology Company, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.
For more information : https://www.akoyabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.